Genetic heterogeneity in multiple myeloma.
In the past decade, many progresses have been made in our knowledge of the genetics of multiple myeloma. The use of molecular cytogenetic techniques has led to the identification of several recurrent (cyto)genetic abnormalities, representing either prognostic markers, or novel therapeutic targets. More global analyses of this genetic heterogeneity using expression array technologies should further extend our understanding of the disease, hopefully enabling some improvements in the treatment of the patients. The goal of this minireview is to summarize these recent advances.
Magrangeas
F
F
Hematology Laboratory, University Hospital, Nantes, France.
Lodé
L
L
Wuilleme
S
S
Minvielle
S
S
Avet-Loiseau
H
H
D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002874:Chromosome Mapping; D002882:Chromosomes, Human, Pair 13; D002883:Chromosomes, Human, Pair 14; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics* / Q000628:therapy; D011003:Ploidies